Table 1.
Antiviral activity of the investigated agents with respect to pseudo-HIV-1 particles pseudotyped with vesicular stomatitis virus G protein
| Agent | Cell line | ID50, µm | |
|---|---|---|---|
| Experimental data | Published data [20–29] | ||
| AZT | Jurkat | 0.1 ± 0.01 | 0.004–0.1 |
| SC-1 | 0.08 ± 0.005 | ||
| Kasumi-1 | 0.3 ± 0.02 | ||
| CEM-SS | 0.46 ± 0.05 | ||
| 3TC | Jurkat | 0.7 ± 0.05 | 0.02–0.35 |
| CEM-SS | 0.85 ± 0.05 | ||
| d4T | Jurkat | 7 ± 0.5 | 0.43–1.67 |
| SC-1 | 10 ± 0.5 | ||
| ddC | Jurkat | 7 ± 0.5 | 0.067–0.316 |
| SC-1 | 5 ± 0.5 | ||
| ddI | Jurkat | > 20 | 1.79–12 |
| SC-1 | > 20 | ||
| Nevirapine | Jurkat | 0.1 ± 0.005 | 0.0072–0.22 |
| SC-1 | 0.15 ± 0.005 | ||
| Kasumi-1 | 0.08 ± 0.005 | ||
| CEM-SS | 0.2 ± 0.01 | ||
| Non-nucleoside inhibitor of RT 1 | Jurkat | 0.95 ± 0.005 | 0.13 |
| Non-nucleoside inhibitor of RT 2 | Jurkat | 0.08 ± 0.001 | 0.016 |
| Non-nucleoside inhibitor of RT 3 | Jurkat | 0.085 ± 0.001 | 0.018 |
| Raltegravir | Jurkat | 0.009 ± 0.0005 | 0.0022–0.0037 |
| SC-1 | 0.006 ± 0.0005 | ||
| CEM-SS | 0.009 ± 0.0005 | ||
| L-731988 | Jurkat | 12 ± 0.1 | 1 |
| SC-1 | 8 ± 0.1 | ||